HMG-CoA Reductase Inhibitors for Hypercholesterolemia

J. A. Tobert; B. R. Leslie; E. J. Schaefer; H. R. Van Buuren; M. G A Baggen; J. H P Wilson; Scott M Grundy

doi:10.1056/NEJM198811033191811

HMG-CoA Reductase Inhibitors for Hypercholesterolemia

J. A. Tobert, B. R. Leslie, E. J. Schaefer, H. R. Van Buuren, M. G A Baggen, J. H P Wilson, Scott M Grundy

Research output: Contribution to journal › Letter › peer-review

50 Scopus citations

Abstract

To the Editor: In his review (July 7 issue)* of inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, Dr. Grundy concluded that these drugs are effective and usually well-tolerated cholesterol-lowering agents. He also pointed out, appropriately, that these compounds have not been given to large populations for long periods and, therefore, their adverse effects may not be fully defined. We would like to provide the interim results, as of May 1988, of a long-term study of lovastatin that began in 1984. In the study, long-term therapy with a lipid-lowering diet plus lovastatin is being evaluated in 744 patients in 23 centers.

Original language	English (US)
Pages (from-to)	1222-1223
Number of pages	2
Journal	New England Journal of Medicine
Volume	319
Issue number	18
DOIs	https://doi.org/10.1056/NEJM198811033191811
State	Published - Nov 3 1988

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM198811033191811

Cite this

@article{b0e1575dc9524a2f886a480629955e04,

title = "HMG-CoA Reductase Inhibitors for Hypercholesterolemia",

abstract = "To the Editor: In his review (July 7 issue)* of inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, Dr. Grundy concluded that these drugs are effective and usually well-tolerated cholesterol-lowering agents. He also pointed out, appropriately, that these compounds have not been given to large populations for long periods and, therefore, their adverse effects may not be fully defined. We would like to provide the interim results, as of May 1988, of a long-term study of lovastatin that began in 1984. In the study, long-term therapy with a lipid-lowering diet plus lovastatin is being evaluated in 744 patients in 23 centers.",

author = "Tobert, {J. A.} and Leslie, {B. R.} and Schaefer, {E. J.} and {Van Buuren}, {H. R.} and Baggen, {M. G A} and Wilson, {J. H P} and Grundy, {Scott M}",

year = "1988",

month = nov,

day = "3",

doi = "10.1056/NEJM198811033191811",

language = "English (US)",

volume = "319",

pages = "1222--1223",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "18",

}

TY - JOUR

T1 - HMG-CoA Reductase Inhibitors for Hypercholesterolemia

AU - Tobert, J. A.

AU - Leslie, B. R.

AU - Schaefer, E. J.

AU - Van Buuren, H. R.

AU - Baggen, M. G A

AU - Wilson, J. H P

AU - Grundy, Scott M

PY - 1988/11/3

Y1 - 1988/11/3

N2 - To the Editor: In his review (July 7 issue)* of inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, Dr. Grundy concluded that these drugs are effective and usually well-tolerated cholesterol-lowering agents. He also pointed out, appropriately, that these compounds have not been given to large populations for long periods and, therefore, their adverse effects may not be fully defined. We would like to provide the interim results, as of May 1988, of a long-term study of lovastatin that began in 1984. In the study, long-term therapy with a lipid-lowering diet plus lovastatin is being evaluated in 744 patients in 23 centers.

AB - To the Editor: In his review (July 7 issue)* of inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, Dr. Grundy concluded that these drugs are effective and usually well-tolerated cholesterol-lowering agents. He also pointed out, appropriately, that these compounds have not been given to large populations for long periods and, therefore, their adverse effects may not be fully defined. We would like to provide the interim results, as of May 1988, of a long-term study of lovastatin that began in 1984. In the study, long-term therapy with a lipid-lowering diet plus lovastatin is being evaluated in 744 patients in 23 centers.

UR - http://www.scopus.com/inward/record.url?scp=0023811877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023811877&partnerID=8YFLogxK

U2 - 10.1056/NEJM198811033191811

DO - 10.1056/NEJM198811033191811

M3 - Letter

C2 - 3173461

AN - SCOPUS:0023811877

SN - 0028-4793

VL - 319

SP - 1222

EP - 1223

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 18

ER -

HMG-CoA Reductase Inhibitors for Hypercholesterolemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this